# A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

> **NCT05416749** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 216 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** 8MW2311

## Key facts

- **NCT ID:** NCT05416749
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-08-05
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 216 (ESTIMATED)
- **Why stopped:** Sponsor development strategy adjustment
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05416749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05416749, "A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05416749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*